-
Teva pharmaceuticals is a global company with a superior strategy of "market takeover", as opposed to local company's strategies of simply prevailing in the marketplace.
-
Perrigo Company plc acquires Omega Pharma Invest N.V.
-
Teva proposes a deal to purchase Mylan for ~$50 million.
-
Dr. Reddy’s Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion.
-
IBM Watson Health Cloud and Teva Pharmaceuticals partner to form the first global pharmaceutical partnership with Watson Health Cloud to benefit healthcare providers and patients
-
DRL received warning letters from the U.S. Food and Drug Administration authorities in November 2015 regarding inadequate quality control procedures at 3 manufacturing plants in India
-
Nov 10, 2015 - Mylan reminds shareholders of Perrigo that its offer to acquire all outstanding shares of Perrigo will expire
-
Chief Executive Joseph Papa leaves months after he helped Perrigo beat back a hostile bid from Mylan
-
Mylan Futures up 4% in second quarter
-
Drug major Dr Reddy's Laboratories has forayed into branded consumer health products segment in the US market by acquiring six over-the-counter (OTC) brands from Ducere Pharma for an undisclosed amount. The brands acquired include Doan's, Bufferin, Nupercainal ointment, Cruex nail gel, comtrex and myoflex. These are mainly used in treating cough-and-cold, pain and dermatology issues.
-
Zack's Investment Research rated Teva Pharmaceuticals down to a "sell" rating from a "hold" rating, saying the company is expected to start going downwards
-
Mylan commits to providing EpiPen to as many people for as cheap as possible
-
Pomerantz LLP announces a class action lawsuit has been filed against Perrigo Company
-
Hyderabad-based pharmaceutical company Dr Reddy’s Laboratories has received approval from the Central Drug Standard Control Organization (CDSCO) to export drugs for the European Union market. In an order dated August 5, CDSCO gave its nod, which will allow Dr Reddy’s to export port 15 active pharmaceutical ingredients (APIs) to the European Union. These drugs are used to treat hypertension, pneumonia, bacterial infection, cardiovascular diseases, migraine, among others.
-
Dr Reddy's announced that it has successfully completed the acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceuticals Industries and an affiliate of Allergan Plc. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of acquisition of Allergan's generics business. In June, the company had entered an agreement with Teva to buy this portfolio of ANDAs for $ 350 million.
-
Justice Department is conducting an antitrust violation investigation against over a dozen pharmaceutical companies, including Teva Pharmaceuticals; shares of Lannett fell in value after this was announced by Bloomberg
-
Mylan shareholder manipulates market to profit off of merger, risking conflict of interest concerns. (Peer Reviewed Scholarly Article)